Although studies in mice or non-human primates are often used to make conclusions about human disease, these species do not always respond in the same way. In fact, recent studies show that acute responses to various types of inflammation are very similar between humans of different genetic backgrounds, but poorly correlate with supposedly equivalent mouse models. Thus, human studies that validate the conclusions made from studies in other species are not only important, but are necessary to understand mechanisms of human disease. Moreover, coordinated animal and human studies allow investigators to learn from each model, develop new hypotheses and design better experiments that in mice, will further dissect mechanisms of disease and |n humans, will validate the conclusions drawn from animal studies, since complex mechanistic studies cannot be ethically proposed in human subjects. Therefore, the goal of the human immunology core will be to enable the performance of human studies that will test key hypotheses of each project proposed in the Ul9 program. To achieve this goal. Core C will recruit human subjects and collect clinical samples and clinical information, validate the antigen-specific B cell tetramers in human clinical samples and provide the clinical infrastructure and research expertise for the analysis of virus-specific B and T cells from human samples. The clinical core will coordinate all aspects of the studies related to direct patient contact and specimen collection for the Projects of the U19

Public Health Relevance

Core C: Human Immunology, will provide the clinical infrastructure, knowledge and expertise to recruit human subjects, collect samples from human subjects and perform experiments using those clinical samples that will directly advance the goals of each of the projects in the U19. -

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-ZL-I (J1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Alabama Birmingham
United States
Zip Code
Ordoñez, Ciara; Savage, Hannah P; Tarajia, Musharaf et al. (2018) Both B-1a and B-1b cells exposed to Mycobacterium tuberculosis lipids differentiate into IgM antibody-secreting cells. Immunology :
Jenks, Scott A; Cashman, Kevin S; Zumaquero, Esther et al. (2018) Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus. Immunity 49:725-739.e6
Nguyen, Trang T T; Graf, Beth A; Randall, Troy D et al. (2017) sIgM-Fc?R Interactions Regulate Early B Cell Activation and Plasma Cell Development after Influenza Virus Infection. J Immunol 199:1635-1646
Meza-Perez, Selene; Randall, Troy D (2017) Immunological Functions of the Omentum. Trends Immunol 38:526-536
Baumgarth, Nicole (2017) A Hard(y) Look at B-1 Cell Development and Function. J Immunol 199:3387-3394
Nguyen, Trang T T; Kläsener, Kathrin; Zürn, Christa et al. (2017) The IgM receptor Fc?R limits tonic BCR signaling by regulating expression of the IgM BCR. Nat Immunol 18:321-333
Savage, Hannah P; Yenson, Vanessa M; Sawhney, Sanjam S et al. (2017) Blimp-1-dependent and -independent natural antibody production by B-1 and B-1-derived plasma cells. J Exp Med 214:2777-2794
Botta, Davide; Fuller, Michael J; Marquez-Lago, Tatiana T et al. (2017) Dynamic regulation of T follicular regulatory cell responses by interleukin 2 during influenza infection. Nat Immunol 18:1249-1260
Nellore, Anoma; Randall, Troy D (2016) Narcolepsy and influenza vaccination-the inappropriate awakening of immunity. Ann Transl Med 4:S29
Tian, Yuan; Cox, Maureen A; Kahan, Shannon M et al. (2016) A Context-Dependent Role for IL-21 in Modulating the Differentiation, Distribution, and Abundance of Effector and Memory CD8 T Cell Subsets. J Immunol 196:2153-66

Showing the most recent 10 out of 24 publications